2012 was an exciting year for TECOS that saw the close of recruitment following randomisation of over 14,700 participants. Of the participating countries, 21 of 38 met or exceeded their recruitment targets. We would like to take this opportunity to thank all those involved in the TECOS trial, and particularly the participants.
TECOS is truly a global trial with 41.4% of participants recruited in Europe, 31.0% in Asia Pacific and 27.6% in the Americas across 653 sites. Patients will continue to be followed until 1300 confirmed composite cardiovascular outcomes have occurred, with results expected in 2015.